title: Molecular basis of reduced pyridoxine 5'-phosphate oxidase catalytic activity in neonatal epileptic encephalopathy disorder.
abstract: Mutations in pyridoxine 5'-phosphate oxidase are known to cause neonatal epileptic encephalopathy. This disorder has no cure or effective treatment and is often fatal. Pyridoxine 5'-phosphate oxidase catalyzes the oxidation of pyridoxine 5'-phosphate to pyridoxal 5'-phosphate, the active cofactor form of vitamin B(6) required by more than 140 different catalytic activities, including enzymes involved in amino acid metabolism and biosynthesis of neurotransmitters. Our aim is to elucidate the mechanism by which a homozygous missense mutation (R229W) in the oxidase, linked to neonatal epileptic encephalopathy, leads to reduced oxidase activity. The R229W variant is approximately 850-fold less efficient than the wild-type enzyme due to an approximately 192-fold decrease in pyridoxine 5'-phosphate affinity and an approximately 4.5-fold decrease in catalytic activity. There is also an approximately 50-fold reduction in the affinity of the R229W variant for the FMN cofactor. A 2.5 A crystal structure of the R229W variant shows that the substitution of Arg-229 at the FMN binding site has led to a loss of hydrogen-bond and/or salt-bridge interactions between FMN and Arg-229 and Ser-175. Additionally, the mutation has led to an alteration of the configuration of a beta-strand-loop-beta-strand structure at the active site, resulting in loss of two critical hydrogen-bond interactions involving residues His-227 and Arg-225, which are important for substrate binding and orientation for catalysis. These results provide a molecular basis for the phenotype associated with the R229W mutation, as well as providing a foundation for understanding the pathophysiological consequences of pyridoxine 5'-phosphate oxidase mutations.
authors.affiliation: Department of Medicinal Chemistry, School of Pharmacy, and Institute for Structural Biology and Drug Discovery, Virginia Commonwealth University, Richmond, Virginia 23219, USA.
authors.forename: Faik N
authors.initials: FN
authors.lastname: Musayev
authors.forename: Martino L
authors.initials: ML
authors.lastname: Di Salvo
authors.forename: Mario A
authors.initials: MA
authors.lastname: Saavedra
authors.forename: Roberto
authors.initials: R
authors.lastname: Contestabile
authors.forename: Mohini S
authors.initials: MS
authors.lastname: Ghatge
authors.forename: Alexina
authors.initials: A
authors.lastname: Haynes
authors.forename: Verne
authors.initials: V
authors.lastname: Schirch
authors.forename: Martin K
authors.initials: MK
authors.lastname: Safo
mesh_terms: D001665:Binding Sites; D002384:Catalysis; D003460:Crystallization; D020936:Epilepsy, Benign Neonatal / Q000201:enzymology* / Q000235:genetics; D005486:Flavin Mononucleotide / Q000737:chemistry; D006801:Humans; D007700:Kinetics; D008968:Molecular Conformation; D020125:Mutation, Missense; D011485:Protein Binding; D011732:Pyridoxal Phosphate / Q000031:analogs & derivatives / Q000737:chemistry; D011734:Pyridoxaminephosphate Oxidase / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism*; D013379:Substrate Specificity
chemical_list: D011732:Pyridoxal Phosphate; D005486:Flavin Mononucleotide; D011734:Pyridoxaminephosphate Oxidase; C024593:pyridoxine 5-phosphate